GLYCOMET TRIO 0.5 TABLET 10'S

Glycomet Trio 0.5 is used for the management of type 2 diabetes mellitus in adults when blood sugar is not adequately controlled with diet, exercise, and single or dual oral antidiabetic therapy. It helps lower fasting and postprandial blood glucose and improve overall glycaemic control as part of a comprehensive diabetes management plan.

Glycomet Trio 0.5 contains three active ingredients: glimepiride (a sulfonylurea that increases insulin secretion from the pancreas), metformin (a biguanide that reduces hepatic glucose production and improves insulin sensitivity, often in sustained-release form), and voglibose (an alpha-glucosidase inhibitor that slows carbohydrate digestion and reduces post-meal glucose spikes).

Glycomet Trio 0.5 works through complementary mechanisms. Glimepiride stimulates pancreatic beta cells to release more insulin. Metformin decreases glucose production by the liver, reduces intestinal glucose absorption, and enhances peripheral insulin sensitivity. Voglibose inhibits intestinal alpha-glucosidase enzymes, delaying the breakdown and absorption of complex carbohydrates, thereby blunting postprandial rises in blood glucose.

Yes. Because Glycomet Trio 0.5 contains glimepiride, it can cause hypoglycaemia, especially if meals are skipped or delayed, caloric intake is reduced, strenuous exercise is undertaken without appropriate carbohydrate intake, or it is combined with other glucose-lowering agents or alcohol. Symptoms include sweating, tremor, palpitations, hunger, headache, dizziness, and confusion. Patients should be instructed on recognising these symptoms and treating them promptly with fast-acting carbohydrates.

Common side effects include gastrointestinal symptoms such as nausea, abdominal discomfort, diarrhoea, flatulence, and a feeling of fullness, which are mainly related to metformin and voglibose. Hypoglycaemia due to glimepiride can also occur. Some patients may experience mild weight gain from the sulfonylurea component, while metformin tends to be weight-neutral. Long-term use of metformin may be associated with reduced vitamin B12 levels in some individuals.

Glycomet Trio 0.5 is generally contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal impairment, significant hepatic dysfunction, known hypersensitivity to any of its components, and in patients with conditions predisposing to lactic acidosis (such as severe heart failure, severe respiratory failure, or acute serious illness with tissue hypoxia). It is not recommended in children. Use in pregnancy and breastfeeding requires specialist assessment, and insulin-based regimens are usually preferred during pregnancy.

Use of Glycomet Trio 0.5 during pregnancy is generally not recommended because sulfonylureas can cross the placenta and may cause neonatal hypoglycaemia, and safety data for voglibose in pregnancy are limited. Metformin is sometimes used in pregnancy under specialist supervision, but fixed-dose triple combinations are usually avoided. Pregnant women or those planning pregnancy should consult an endocrinologist or obstetrician; insulin is typically the treatment of choice for tight glycaemic control in pregnancy.

Caution is required in patients with renal impairment because metformin is renally excreted and accumulation can lead to lactic acidosis, a rare but serious complication. In moderate to severe renal impairment, metformin-containing products may be contraindicated or require dose adjustment and close monitoring, and fixed-dose combinations may not be appropriate. Glimepiride exposure is also increased in renal dysfunction, raising the risk of hypoglycaemia. Kidney function (eGFR or creatinine clearance) should be assessed before starting therapy and periodically thereafter, and any decision to use this medicine must be made by a physician.

Alcohol intake should be limited or avoided while taking Glycomet Trio 0.5. Excessive alcohol consumption, acute or chronic, increases the risk of metformin-associated lactic acidosis and can also potentiate hypoglycaemia with glimepiride. If alcohol is consumed, it should be in moderation and with food, and patients should be counselled on the signs of hypoglycaemia and lactic acidosis and advised to seek medical attention if concerning symptoms occur.

If a dose is missed, it should generally be taken as soon as the patient remembers, provided it is still close to the usual dosing time and associated meal. If it is almost time for the next scheduled dose, the missed dose should be skipped and the regular dosing schedule resumed. Double dosing to make up for a missed dose should be avoided, as this increases the risk of hypoglycaemia and gastrointestinal side effects. Patients with frequent missed doses should discuss adherence strategies with their healthcare provider.

Glycomet Trio 0.5 may be used in combination with other antidiabetic agents, including insulin, in selected patients under specialist supervision. However, combining multiple glucose-lowering drugs increases the risk of hypoglycaemia and other adverse effects. Any addition or change in therapy should be guided by a physician based on current glycaemic control, comorbidities, and risk profile. Patients should not add or stop antidiabetic medicines on their own without medical advice.